Cargando…
Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
OBJECTIVE. To describe the immunogenicity and safety of a tetravalent dengue vaccine (TAK-003) in healthy adolescents living in Mexico City, an area considered non-endemic for dengue (NCT03341637). METHODS. Participants aged 12–17 years were randomized 3:1 to receive two doses (Month 0 and Month 3)...
Autores principales: | Biswal, Shibadas, Mendez Galvan, Jorge Fernando, Macias Parra, Mercedes, Galan-Herrera, Juan-Francisco, Carrascal Rodriguez, Monica Belisa, Rodriguez Bueno, Esteban Patricio, Brose, Manja, Rauscher, Martina, LeFevre, Inge, Wallace, Derek, Borkowski, Astrid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Organización Panamericana de la Salud
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196333/ https://www.ncbi.nlm.nih.gov/pubmed/34131423 http://dx.doi.org/10.26633/RPSP.2021.67 |
Ejemplares similares
-
Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023) -
Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
por: LeFevre, Inge, et al.
Publicado: (2023) -
Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study
por: Tricou, Vianney, et al.
Publicado: (2023) -
97. Tetravalent Dengue Vaccine (TAK-003) Development Program: A Bird’s Eye View
por: Tricou, Vianney, et al.
Publicado: (2021) -
Safety of Dengue Vaccine?
por: Biswal, Shibadas, et al.
Publicado: (2022)